These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6217773)

  • 21. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry.
    Raz N; Torres IJ; Briggs SD; Spencer WD; Thornton AE; Loken WJ; Gunning FM; McQuain JD; Driesen NR; Acker JD
    Neurology; 1995 Feb; 45(2):356-66. PubMed ID: 7854539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.
    Rumble B; Retallack R; Hilbich C; Simms G; Multhaup G; Martins R; Hockey A; Montgomery P; Beyreuther K; Masters CL
    N Engl J Med; 1989 Jun; 320(22):1446-52. PubMed ID: 2566117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons.
    Oka A; Takashima S
    Neuroreport; 1997 Mar; 8(5):1161-4. PubMed ID: 9175105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down's syndrome as a model disease.
    Scoggin CH; Patterson D
    Arch Intern Med; 1982 Mar; 142(3):462-4. PubMed ID: 6461305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's disease pathogenesis: role of aging.
    Harman D
    Ann N Y Acad Sci; 2006 May; 1067():454-60. PubMed ID: 16804026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Down's syndrome and dementia].
    Parajuá-Pozo JL; Casis-Arguea S
    Rev Neurol; 2000 Jul 16-31; 31(2):126-8. PubMed ID: 10951667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of alterations in free radical metabolism in mediating cognitive impairments in Down's syndrome.
    Brugge KL; Nichols S; Delis D; Saitoh T; Truaner D
    EXS; 1992; 62():190-8. PubMed ID: 1450586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.
    Alexandrov PN; Percy ME; Lukiw WJ
    Cell Mol Neurobiol; 2018 Apr; 38(3):769-774. PubMed ID: 28687876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating immune complexes in sera from patients with Alzheimer's disease, multi-infarct dementia and Down's syndrome.
    Heinonen O; Syrjänen S; Soininen H; Talasniemi S; Kaski M; Mäntyjärvi R; Syrjänen K; Riekkinen P
    Neurosci Lett; 1993 Jan; 149(1):67-70. PubMed ID: 8469384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.
    Anderson-Mooney AJ; Schmitt FA; Head E; Lott IT; Heilman KM
    Brain Cogn; 2016 Apr; 104():48-57. PubMed ID: 26930369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-related neuropsychological deficits in Down's syndrome.
    Thase ME; Tigner R; Smeltzer DJ; Liss L
    Biol Psychiatry; 1984 Apr; 19(4):571-85. PubMed ID: 6234031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.
    Teipel SJ; Alexander GE; Schapiro MB; Möller HJ; Rapoport SI; Hampel H
    Brain; 2004 Apr; 127(Pt 4):811-24. PubMed ID: 14985261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytogenetic study and chromosome abnormalities of Alzheimer's disease and Down's syndrome].
    Asaka A
    Nihon Rinsho; 1988 Jul; 46(7):1502-7. PubMed ID: 2975715
    [No Abstract]   [Full Text] [Related]  

  • 34. Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.
    Wilcock DM; Schmitt FA; Head E
    Biochim Biophys Acta; 2016 May; 1862(5):909-14. PubMed ID: 26593849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymic deficiency in Down's syndrome.
    Levin S; Schlesinger M; Handzel Z; Hahn T; Altman Y; Czernobilsky B; Boss J
    Pediatrics; 1979 Jan; 63(1):80-7. PubMed ID: 155804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus.
    Furuta A; Price DL; Pardo CA; Troncoso JC; Xu ZS; Taniguchi N; Martin LJ
    Am J Pathol; 1995 Feb; 146(2):357-67. PubMed ID: 7856748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alzheimer's disease and Down's syndrome: a review].
    Vicari S; Caltagirone C
    Riv Neurol; 1990; 60(4):151-9. PubMed ID: 2151240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukocyte lysosomal enzymes in Alzheimer's disease and Down's syndrome.
    Kalanj-Bognar S; Rundek T; Furac I; Demarin V; Cosović C
    J Gerontol A Biol Sci Med Sci; 2002 Jan; 57(1):B16-21. PubMed ID: 11773202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid function and plasma immunoglobulins in subjects with Down's syndrome (DS) during ontogenesis and zinc therapy.
    Sustrová M; Strbák V
    J Endocrinol Invest; 1994 Jun; 17(6):385-90. PubMed ID: 7930384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.